

Cancer

Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors

Trial Status
Completed

Trial Runs In
7 Countries

Trial Identifier
NCT02639546 2014-004685-25
GO29665

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This open-label, dose-escalation study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of cobimetinib in pediatric and young adult participants with solid tumors with known or potential kinase pathway activation for which standard therapy has proven to be ineffective or intolerable or for which no curative standard-of-care treatment options exist. The study will be conducted in two stages: a dose-escalation stage and an expansion stage at the recommended dose.

Hoffmann-La Roche
Sponsor

Phase 1/Phase 2
Phase

NCT02639546 2014-004685-25 GO29665
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>= 6 Months & <= 30 Years

Healthy Volunteers
No